In summary, by integrating perturbation signatures with gene expression data of primary tumors and cancer cell lines with matched drug sensitivity data, we have been able to identify a novel clinically relevant subtype of ER+ breast cancer, as well as a targeted treatment (a PIK3/AKT/mTOR inhibitor) that is likely to benefit this specific patient subgroup. This evidence concerns the gene AKT1 and cancer.